Last reviewed · How we verify
Lactobacillus reuteri 17938 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Lactobacillus reuteri 17938 (Lactobacillus reuteri 17938) — Tulane University School of Medicine.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Lactobacillus reuteri 17938 TARGET | Lactobacillus reuteri 17938 | Tulane University School of Medicine | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Lactobacillus reuteri 17938 CI watch — RSS
- Lactobacillus reuteri 17938 CI watch — Atom
- Lactobacillus reuteri 17938 CI watch — JSON
- Lactobacillus reuteri 17938 alone — RSS
Cite this brief
Drug Landscape (2026). Lactobacillus reuteri 17938 — Competitive Intelligence Brief. https://druglandscape.com/ci/lactobacillus-reuteri-17938. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab